Gossamer Bio, Inc.
seralutinib
pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Countdown
237days
Approval decision · Mar 1, 2027
What's at stake
A final FDA approval decision on seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) is expected Mar 1, 2027.
Primary source
· SEC 8-K
verified 13h ago
“If the NDA is accepted for filing, seralutinib could be eligible for FDA approval in the third quarter of 2027.”